7wpv
Fab14 - a SARS-CoV2 RBD neutralising antibody
Structural highlights
Publication Abstract from PubMedOne major limitation of neutralizing antibody-based COVID-19 therapy is the requirement of costly cocktails to reduce emergence of antibody resistance. Here we engineer two bispecific antibodies (bsAbs) using distinct designs and compared them with parental antibodies and their cocktail. Single molecules of both bsAbs block the two epitopes targeted by parental antibodies on the receptor-binding domain (RBD). However, bsAb with the IgG-(scFv)(2) design (14-H-06) but not the CrossMAb design (14-crs-06) shows increased antigen-binding and virus-neutralizing activities against multiple SARS-CoV-2 variants as well as increased breadth of neutralizing activity compared to the cocktail. X-ray crystallography and cryo-EM reveal distinct binding models for individual cocktail antibodies, and computational simulations suggest higher inter-spike crosslinking potentials by 14-H-06 than 14-crs-06. In mouse models of infections by SARS-CoV-2 and multiple variants, 14-H-06 exhibits higher or equivalent therapeutic efficacy than the cocktail. Rationally engineered bsAbs represent a cost-effective alternative to antibody cocktails and a promising strategy to improve potency and breadth. Engineering SARS-CoV-2 specific cocktail antibodies into a bispecific format improves neutralizing potency and breadth.,Ku Z, Xie X, Lin J, Gao P, Wu B, El Sahili A, Su H, Liu Y, Ye X, Tan EY, Li X, Fan X, Goh BC, Xiong W, Boyd H, Muruato AE, Deng H, Xia H, Zou J, Kalveram BK, Menachery VD, Zhang N, Lescar J, Shi PY, An Z Nat Commun. 2022 Sep 22;13(1):5552. doi: 10.1038/s41467-022-33284-y. PMID:36138032[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
| ||||||||||||||||||
